Pfizer licenses CAR-T therapies from China's Starna in up to $2.6 billion deal
Pfizer has signed an exclusive licensing deal with China's Starna Therapeutics for three CAR-T therapies targeting autoimmune diseases, potentially worth up to $2.6 billion. Pfizer will pay $330 million upfront and additional milestone payments. The therapies are in early stages, with no human trials yet. This deal is part of Pfizer's strategy to boost growth by 2028 amid patent expirations and declining COVID-related revenue.
How this was made

The 30-second read
Why it matters
The agreement provides Pfizer ex-Greater China development and commercialization rights, with initial clinical trial supplies manufactured at Pfizer’s US facilities. Financially, it includes a $330M upfront payment and up to $2.3B additional milestone payments plus royalties on sales.
Market read
Traders can reassess Pfizer’s pipeline trajectory and capital allocation based on the deal’s size and the fact that the programs are pre-human trials.
What to watch
Investors may focus on execution risk (manufacturing, trial design, regulatory path) and on how this licensing spend fits Pfizer’s broader portfolio and cash-flow needs through 2028.
Background
Pfizer is seeking to reignite growth by 2028 while preparing for patent expirations and ongoing declines in COVID-related revenue. This licensing adds three early-stage autoimmune CAR-T programs from Starna.
Ticker impact
Pfizer struck an exclusive licensing deal to develop three Starna CAR-T autoimmune therapies, paying $330M upfront and up to $2.3B more on milestones.
Likely modest positive bias as investors price in pipeline expansion and deal scale, tempered by early-stage uncertainty and milestone-based cash outflows.
The article discloses a large upfront payment and total deal value, plus commercialization rights outside Greater China, which are tangible catalysts. However, it also states the therapies have not entered human trials, limiting near-term earnings visibility.
Market effects
Highlights continued pharma interest in CAR-T and autoimmune indications, potentially supporting sentiment for cell-therapy platforms and licensing activity.
Deal grants Pfizer rights outside Greater China, implying competitive positioning in ex-China autoimmune cell-therapy development.
Large cross-border licensing underscores ongoing globalization of biotech R&D and capital allocation despite patent-expiration headwinds.
Counterpoint
The deal may be viewed as a costly, high-risk bet with limited near-term revenue impact because the programs are early-stage and milestone payments depend on successful development.
Key entities
- companyPfizer
US pharma company entering an exclusive licensing agreement for three Starna CAR-T therapies in autoimmune diseases.
- companyStarna Therapeutics
China-based biotech licensing its early-stage CAR-T autoimmune programs to Pfizer.



